Soranib tablet 200 mg 30’s

Frequently asked questions

• Onset of action

  The peak effect of this medicine can be observed within 3 hours of administration of the dose.

• Duration of Effect

  The amount of time for which this medicine remains active in the body is not clinically established.

• Safe with Alchohol?

  Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

• Is it habit forming?

  No habit-forming tendencies were reported.

• Usage in pregnancy?

  This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

• Usage while breast-feeding?

  This medicine is not recommended for use in breastfeeding women. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition

• Allergy

  This medicine is not recommended for use in patients with a known allergy to Soranib tablet 200 mg 30’s or any other inactive ingredients present along with it.

• Squamous cell lung cancer

  This medicine is not recommended for use with carboplatin and paclitaxel in patients with squamous cell lung cancer due to the increased risk of worsening of the patient's condition.

• Pregnancy

  This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

• Breast-feeding

  This medicine is not recommended for use in breastfeeding women. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition

• Dermatological toxicities

  Hand-foot skin reaction and rash represent the most common adverse drug reactions with this medicine which generally appear during the first six weeks of treatment. Management of dermatological toxicities may include topical therapies for symptomatic relief, temporary treatment discontinuation and/or dose modification, or in severe or persistent cases, permanent discontinuation of the treatment.

• Hypertension

  This medicine should be used with caution due to the increased risk of hypertension. It is usually mild to moderate, occurred early in the course of treatment, which is usually managed with standard antihypertensive therapy. Blood pressure should be monitored regularly while receiving this medicine. In cases of severe or persistent hypertension, or hypertensive crisis despite institution of antihypertensive therapy, permanent discontinuation of Soranib Tablet should be considered.

• Hypoglycemia

  This medicine should be used with caution due to the increased risk of low blood glucose levels. In the case of symptomatic hypoglycemia, Soranib Tablet should be temporarily interrupted. Blood glucose levels in diabetic patients should be monitored regularly in order to assess if anti-diabetic medicinal product's dosage needs to be adjusted. An alternative treatment option should be considered in some cases based on the clinical condition.

• Bleeding

  Increased risk of bleeding may occur with this medicine. It is advised to discontinue this medicine in case of serious bleeding events. Thyroid cancer patients with tracheal, bronchial, and esophageal infiltration should be treated with local therapy prior to administering this medicine due to the potential bleeding risk.

• Heart Diseases

  This medicine should be used with caution in patients with cardiac diseases due to the increased risk of decreased blood flow to the heart or heart attack. It is advised to discontinue the therapy (temporary or permanent) in patients who develop these conditions.

• Driving or Operating machinery

  Use of this medicine may cause dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience dizziness during the treatment with this medicine.

• Use in Children

  This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Take Soranib Tablet exactly as prescribed by the doctor. Do not take in larger or smaller quantities than recommended. Take this medicine at least 1 hour before or 2 hours after the meal. You may require frequent blood tests and liver function tests while taking this medicine. You may also require frequent followups with your doctor to check the progress of treatment. Do not stop the use of this medicine without consulting your doctor.

• medlineplus.gov - Sorafenib [Internet]. Available from: https://medlineplus.gov/druginfo/meds/a607051.html [cited 28/7/2020]. 2020